Low somatostatin receptor subtype 2, but not dopamine receptor subtype 2 expression predicts the lack of biochemical response of somatotropinomas to treatment with somatostatin analogs

L. E A Wildemberg, L. V. Neto, D. F. Costa, L. E. Nasciuti, C. M. Takiya, L. M. Alves, A. Rebora, F. Minuto, D. Ferone, M. R. Gadelha

Research output: Contribution to journalArticlepeer-review

Abstract

Objectives: To evaluate somatostatin receptor 2A (SSTR2A) and dopamine receptor 2 (DR2) protein expression in somatotropinomas and to relate it to response to somatostatin analogues (SA). Design and patients: SSTR2A and DR2 expression was analyzed by immunohistochemistry in 88 somatotropinomas from patients submitted to either pre-surgical or adjuvant SA treatment. Tumors were scored according to percentage of immunostained cells: 0 (50%). Relation between protein expression and response to SA was performed in 66 patients. Response to SA was assessed by percent IGF-I reduction, being considered as an IGF-I per cent reduction higher than 50%. Disease control was also assessed (GH

Original languageEnglish
Pages (from-to)38-43
Number of pages6
JournalJournal of Endocrinological Investigation
Volume36
Issue number1
DOIs
Publication statusPublished - Jan 2013

Keywords

  • Acromegaly
  • Dopamine receptors
  • Immunohistochemistry
  • Somatostatin analogues
  • Somatostatin receptors

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Fingerprint Dive into the research topics of 'Low somatostatin receptor subtype 2, but not dopamine receptor subtype 2 expression predicts the lack of biochemical response of somatotropinomas to treatment with somatostatin analogs'. Together they form a unique fingerprint.

Cite this